Nonprofit founder and CEO, Craig Martin, notes that the industry will likely see more alternative gene therapy commercialisation models in the future.
BridgeBio Pharma's fair value estimate has nudged higher to roughly $84.65 per share, as analysts bake in slightly stronger revenue growth assumptions of about 80.8% driven by better than expected ...
Abstract: This letter presents an ultra-wideband 20–42 GHz image-reject up-conversion mixer with low dc-power consumption implemented in 55 nm CMOS technology for multiband mm-Wave 5G systems. A ...
You are free to share (copy and redistribute) this article in any medium or format within the parameters below: Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback